Issue link: https://resources.nanotempertech.com/i/1527198
About Pierre Fabre Founded in 1962 by Mr. Pierre Fabre, Laboratoires Pierre Fabre is an international pharmaceutical and dermo-cosmetic group. The Pierre Fabre Immunology Center, part of its Medical Care subsidiary, focuses on researching monoclonal antibodies for cancer treatment. How Pierre Fabre Laboratories enhances their antibody developability platform with Prometheus Panta The Situation Dr. Elsa Wagner, a senior discovery scientist for biologics characterization & developability at Pierre Fabre Laboratories (Saint-Julien-en-Genevois, France), is building a developability platform for monoclonal antibodies (mAbs) in immuno-oncology. She wants to enhance her existing in-silico, in-vitro, and in-vivo methods, helping to select and optimize mAb candidates for clinical development. To achieve this, Dr. Wagner seeks to profile mAb stability by measuring key parameters like thermal unfolding, particle sizing, and aggregation. The Challenge While additional lead information helps in identifying top candidates, handling large libraries of hits requires an efficient, precise, and reproducible developability platform. Using multiple tools increases measurement time, handling complexity, and sample consumption. Therefore Dr. Wagner's goal is to get a single tool providing multiple physicochemical properties that maintain the high data precision and reproducibility needed for reliable hit and lead characterization. This approach also ensures her platform's adaptability across various projects. Summary Situation: At Pierre Fabre Immunology Center (CIPF), senior scientist Dr. Elsa Wagner seeks additional criteria for more confident monoclonal antibody (mAb) candidate selection during developability assessment. Challenge: To enhance efficiency, she aims to measure multiple physico-chemical stability parameters quickly and with minimal sample consumption. Solution: The Prometheus Panta provides simultaneous, high-resolution thermal and colloidal stability measurements. It determines melting temperatures via nanoDSF, particle sizing and purity with DLS, and monitors aggregate formation through backreflection. Results & Benefits: Multi-parameter stability measurements of mAb libraries on Prometheus Panta streamline her developability platform, reducing complexity, cost, and sample consumption, all while generating more valuable data. By correlating the melting temperature (Tm) of the Fab region with the onset of aggregate formation, Dr. Wagner and her team confidently rank mAbs to select the best candidates for further clinical development. Prometheus Panta is a must-have equipment for mAb characterization. It perfectly fits into our developability platform and allows new criteria to be introduced upstream of the candidate selection process. Dr. Elsa Wagner Senior Scientist, Pierre Fabre C A S E S T U D Y © 2024 NanoTemper Technologies, GmbH, Munich, Germany. All Rights Reserved.